Bionoia Where life meets thought ⌕
Back to Journal
Journal › Mucosa
Interventions

FMT — fecal microbiota transplantation

Evidence Mechanism review
microbiome intervention technique barrier cdi
Editor's note
Recurrent C. difficile infection now has a durable, microbiota-based solution: FMT resolves 81–95% of cases, making it the evidence standard for patients who relapse after antibiotic courses. While this indication is established, the mechanism—restoring barrier-protective bacteria rather than continuing antimicrobial cycles—points toward how future mucosal therapies might work. Infectious disease specialists and gastroenterologists should consider FMT early in recurrent CDI, though broader applications in IBD and barrier disorders remain investigational.

FMT has moved from experimental to standard treatment for specific indications.

FMT resolution of recurrent C. difficile infection: 81–95% across academic and private settings. FMT is safe and effective for recurrent CDI. Recurrence after first CDI treatment is 15–20%, rising to 60% after first recurrence. Given the intestinal microbiota's role in CDI susceptibility, FMT has emerged as a therapy to modify this risk without antibiotics.

For non-CDI indications (IBD, chronic barrier dysfunction), evidence is less strong but growing. In Denmark, FMT is performed primarily at Hvidovre Hospital and Aarhus University Hospital.

Related articles in this corpus

Parallel
Pharmacomicrobiomics of Non-Antibiotic Drugs: Mechanisms and Clinical Consequences of Gut Microbiota Alterations
Both articles address how non-antibiotic interventions (FMT in A, drugs in B) alter gut microbiota composition with clinical consequences, but operate at different levels—A focuses on microbiota transplantation as therapy while B examines drug-induced microbiota alterations as pharmacological side effects.
Parallel
Microbiota remodeling after bariatric surgery: Procedure-specific dynamics and metabolic implications
Both articles examine gut microbiota modification as a mechanism for therapeutic benefit in metabolic and gastrointestinal conditions, but through different interventions (FMT versus bariatric surgery) and disease targets.
Parallel
Multi-omics Analysis Reveals the Protection of a Quadruple Probiotic Mixture in Experimental Autoimmune Hepatitis
Both articles address microbiota-based interventions (FMT vs probiotics) for different immune-mediated conditions, sharing the mechanistic premise that gut microbiota modification can treat inflammatory diseases, but pursuing distinct therapeutic approaches.
Parallel
Beyond intestinal failure: Expanding therapeutic frontiers of glucagon-like peptide-2 in gastrointestinal disease
Both articles address distinct therapeutic interventions for gastrointestinal dysfunction—FMT targeting microbiota-mediated disease and GLP-2 targeting intestinal adaptation—with no direct mechanistic overlap or dependency.
Extends
Fecal Microbiota Transplant for Anorexia Nervosa
Article B extends Article A's framework by testing FMT's therapeutic potential in a novel non-CDI indication (anorexia nervosa), building on the established safety profile and microbiota-modification mechanism demonstrated for CDI and other conditions in Article A.
Published 2026-05-24 · Last kit-update 2026-05-24